OncoMatch

OncoMatch/Clinical Trials/NCT07086469

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Is NCT07086469 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Neoadjuvant immunochemotherapy and Surufatinib Administration for toripalimab.

Phase 2RecruitingSun Yat-sen UniversityNCT07086469Data as of May 2026

Treatment: Neoadjuvant immunochemotherapy · Surufatinib Administration · Concurrent Chemotherapy — The combination of surufatinib with neoadjuvant chemo-immunotherapy and definitive concurrent chemoradiotherapy represents a promising new therapeutic strategy that may further improve the prognosis of patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Therefore, we propose to conduct a prospective, single-arm, phase II clinical trial to evaluate the efficacy and safety of this regimen in patients with unresectable, locally advanced ESCC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Esophageal Carcinoma

Disease stage

Required: Stage M1 (LIMITED TO SUPRACLAVICULAR LYMPH NODE METASTASIS)

Locally advanced, unresectable esophageal cancer...staged as T2-4, N0-3, M0-1 (M1 limited to supraclavicular lymph node metastasis).

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

Cannot have received: radiotherapy

Cannot have received: surgery

Cannot have received: targeted therapy

Cannot have received: immunotherapy

Lab requirements

Blood counts

anc ≥ 1.5 × 10⁹/l; platelet count ≥ 100 × 10⁹/l; hemoglobin ≥ 90 g/l

Kidney function

creatinine clearance ≥ 50 ml/min calculated by the cockcroft-gault formula

Liver function

total bilirubin ≤ 1.5 × uln; alt and ast ≤ 2.5 × uln

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify